LONDON & NEW YORK--(BUSINESS WIRE)--ViroCell Biologics (“ViroCell” or the “Company”), a specialist viral vector Contract Development and Manufacturing Organisation (“CDMO”) for cell and gene therapy ...
Cell and gene therapies rely on engineered viruses to deliver them to their cellular destinations. While the progress of these types of medicines is evident in a growing number of FDA product ...
Lentiviral Vector CDMO Market sees 8% CAGR as gene therapy pipeline and R&D investments grow by 2030
The global lentiviral vector CDMO market is set to witness a growth rate of 8% in the next 5 years. Growing demand for gene and cell therapies; expanding pipeline of gene therapy products; ...
Oxford Biomedica and Novartis have agreed to extend an agreement to manufacture lentiviral vectors for several of the Swiss drugmaker’s CAR-T therapies. The move extends the partners' collaboration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results